Literature DB >> 11676304

Prevention and management of antineoplastic-induced hypersensitivity reactions.

K M Zanotti1, M Markman.   

Abstract

Acute hypersensitivity reactions (HSRs) are an unpredictable and potentially catastrophic complication of treatment with chemotherapeutic agents. Reactions may affect any organ system in the body and range widely in severity from mild pruritus to systemic anaphylaxis. Certain classes of chemotherapeutic agents, such as the taxanes, platinum compounds, asparaginases, and epipodophyllotoxins are commonly associated with HSRs. The clinical characteristics of these high risk agents with respect to HSRs are discussed in this review. Protocols to prevent or reduce the severity of these reactions have been developed, but despite these attempts, HSRs will still happen. Should a reaction occur, it is imperative that it be recognised quickly in order to minimise exposure to the inciting agent and implement appropriate therapeutic and supportive measures. When a patient becomes sensitised to a chemotherapeutic agent, avoidance of re-exposure is the mainstay of future prevention. For sensitised patients who have derived clinically meaningful benefit from a particular agent, however, continuation of treatment with the agent is desirable. Options may include attempting a trial of desensitisation or treatment with a related compound. Virtually all patients demonstrating HSRs to paclitaxel and docetaxel are able to successfully tolerate re-treatment following discontinuation and administration of diphenhydramine and hydrocortisone. Re-treatment has generally been less successful with platinum compounds. with recurrent HSRs occurring in up to 50% of patients following desensitisation protocols. Patients sensitised to asparaginase are often able to tolerate the alternative preparations, Erwinia carotovora asparaginase or polyethylene glycol-modified Escherichia coli asparaginase. There is very little experience with re-treatment following sensitisation to the epipodophyllotoxins. As re-treatment may have serious consequences, careful consideration of the risks and benefits of these strategies is imperative when deciding among these options.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11676304     DOI: 10.2165/00002018-200124100-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.228


  59 in total

1.  The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.

Authors:  B L Asselin
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

2.  Weekly schedules of docetaxel.

Authors:  H Burris
Journal:  Semin Oncol       Date:  1998-12       Impact factor: 4.929

3.  [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].

Authors:  B Sikorska-Fic; K Makowska; R Rokicka-Milewska
Journal:  Wiad Lek       Date:  1998

4.  Life-threatening carboplatin hypersensitivity during conditioning for autologous PBSC transplantation: successful rechallenge after desensitization.

Authors:  H Kook; K M Kim; S H Choi; B S Choi; H J Kim; S Y Chung; S J Choi; T J Hwang
Journal:  Bone Marrow Transplant       Date:  1998-04       Impact factor: 5.483

5.  Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.

Authors:  H J Müller; L Löning; A Horn; D Schwabe; M Gunkel; M Schrappe; V von Schütz; G Henze; J Casimiro da Palma; J Ritter; J P Pinheiro; M Winkelhorst; J Boos
Journal:  Br J Haematol       Date:  2000-08       Impact factor: 6.998

6.  Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

Authors:  C J Langer; J C Leighton; R L Comis; P J O'Dwyer; C A McAleer; C A Bonjo; P F Engstrom; S Litwin; R F Ozols
Journal:  J Clin Oncol       Date:  1995-08       Impact factor: 44.544

7.  Hypersensitivity reactions to teniposide (VM-26): an analysis.

Authors:  P J O'Dwyer; S A King; C L Fortner; B Leyland-Jones
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

Review 8.  Hypersensitivity reactions.

Authors:  R B Weiss
Journal:  Semin Oncol       Date:  1992-10       Impact factor: 4.929

9.  Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.

Authors:  E Tomiak; M J Piccart; J Kerger; S Lips; A Awada; D de Valeriola; C Ravoet; D Lossignol; J P Sculier; V Auzannet
Journal:  J Clin Oncol       Date:  1994-07       Impact factor: 44.544

10.  Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent.

Authors:  W Lorenz; H J Reimann; A Schmal; P Dormann; B Schwarz; E Neugebauer; A Doenicke
Journal:  Agents Actions       Date:  1977-03
View more
  27 in total

1.  The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.

Authors:  Dwight D Kloth; Lew Iacovelli; Rebecca Arbuckle; Angela C McIntosh
Journal:  P T       Date:  2010-04

2.  Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients.

Authors:  Alberto Farolfi; Corradina Della Luna; Angela Ragazzini; Elisa Carretta; Nicola Gentili; Carla Casadei; Michele Aquilina; Domenico Barone; Martina Minguzzi; Dino Amadori; Oriana Nanni; Giampaolo Gavelli
Journal:  Oncologist       Date:  2014-07-25

3.  Doxorubicin and Dacarbazine (AD) Regimen for Soft Tissue Sarcomas.

Authors:  Kyle E Adkins; Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2015-03

4.  Recent studies that influence the chemotherapeutic paradigm in the management of advanced ovarian cancer.

Authors:  Maurie Markman
Journal:  F1000 Med Rep       Date:  2010-04-27

Review 5.  Hypersensitivity reactions to chemotherapeutic drugs.

Authors:  Gillian M Shepherd
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

6.  Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.

Authors:  Maurie Markman; Fred Hsieh; Kristine Zanotti; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Ann Spicel; Jerome Belinson
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-15       Impact factor: 4.553

7.  Docetaxel and Cisplatin regimen for non-small-cell lung cancer.

Authors:  Jessie Yang; Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2013-07

8.  Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations.

Authors:  J Boulanger; J N Boursiquot; G Cournoyer; J Lemieux; M S Masse; K Almanric; M P Guay
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

9.  Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.

Authors:  Manojkumar Bupathi; Joud Hajjar; Stacie Bean; Siqing Fu; David Hong; Daniel Karp; Bettzy Stephen; Kenneth Hess; Funda Meric-Bernstam; Aung Naing
Journal:  Invest New Drugs       Date:  2016-09-29       Impact factor: 3.850

10.  Life-threatening adverse drug reactions at admission to medical intensive care: a prospective study in a teaching hospital.

Authors:  Marieke Grenouillet-Delacre; Hélène Verdoux; Nicholas Moore; Françoise Haramburu; Ghada Miremont-Salamé; Gabriel Etienne; Philip Robinson; Didier Gruson; Gilles Hilbert; Claude Gabinski; Bernard Bégaud; Mathieu Molimard
Journal:  Intensive Care Med       Date:  2007-07-25       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.